US In­ter­na­tion­al Trade Com­mis­sion takes on Eli Lil­ly's tirzepatide case

The US In­ter­na­tion­al Trade Com­mis­sion is open­ing an in­ves­ti­ga­tion in­to the al­leged sale of un­ap­proved ver­sions of Eli Lil­ly’s weight loss and di­a­betes drug tirzepatide.

The in­ves­ti­ga­tion stems from a com­plaint filed by Lil­ly in Oc­to­ber against sev­er­al on­line phar­ma­cies im­port­ing or sell­ing what Lil­ly claimed are un­ap­proved ver­sions of tirzepatide be­ing “false­ly and mis­lead­ing­ly mar­ket­ed” as Moun­jaro equiv­a­lents. Tirzepatide is mar­ket­ed as Moun­jaro in type 2 di­a­betes and re­cent­ly launched as Zep­bound in obe­si­ty, though off-la­bel use of Moun­jaro for weight loss led to months-long short­ages this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER